FORMULATION DEVELOPMENT – Next-Generation PEGylation Enables Reduced Immunoreactivity of PEG-Protein Conjugates
Merry R. Sherman, PhD; Mark G.P. Saifer, PhD; L. David Williams, PhD; Shawnya J. Michaels, MS; and Monika A. Sobczyk, MS; illustrate the close parallels between the results of Armstrong et al with respect to anti-PEG antibodies detected in sera of ALL patients treated with mPEG-asparaginase and the results reported by Sundy et al based on the Phase III clinical trials of mPEG-uricase in patients with RCG
Dr. Rod Ray, CEO and Chairman at Bend Research, discusses his company’s approach to difficult drug delivery challenges and the core technologies offered by his company.
Dr. Jean-Luc Herbeaux, the Head of the Health Care Business Line of Evonik, discusses the rationale and success of his company’s latest acquisition.
EXECUTIVE INTERVIEW – Ezose Sciences: High-Throughput Glycomics for Biomarker Discovery – Bringing Glycan Analysis Into Everyday Research
Scott Siegel, PhD, VP of Business Development at Ezose, discusses how his unique company is catalyzing progress across an emerging research front.
Jos Raats, PhD, says ModiQuest has undertaken a number of studies into specific anti-Citrulline antibodies and has discovered a subset (family) of rCit-hMabs, which could provide a valuable therapeutic in the treatment of early onset RA.
Carl Levoguer, PhD, examines how laser diffraction technology has been fashioned to powerfully support every stage of the drug development cycle.
Robert Gwozdz, MPharm, presents an overview of polymers used in the more exotic and technically challenging dosage forms involving MR as well as those used for enhancing the dissolution and bioavailability of poorly soluble APIs.
Mr. Ben Moga, President of Ratio, Inc., talks about his company’s focus on self-injection in a homecare setting and how Ratio is pitting the patch injector against conventional autoinjectors in what is projected to be a $15.8 billion injectable drug delivery device market.
Contributor Cindy H. Dubin posed a series of questions to several CDMOs to find out how they are positioned to help Pharma navigate the waters of patent expirations, rising costs, shrinking timelines, and budget constraints.
DRUG DEVELOPMENT – Design & Development of Atorvastatin Orally Disintegrating Tablets & Their Evaluation by Electronic Tongue
Rakesh Kumar Bhasin, MPharm, and Pradip Kumar Ghosh, PhD, design and develop a good taste-masked atorvastatin ODT that matched the in vitro release profile of Lipitor.
EXCLUSIVE ONLINE CONTENT
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
Alkahest, Inc. recently announced the initiation of a Phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first….
William Small, PhD, and Arsalan Khan say drug degradation can have toxicological effects in many instances, and it is imperative that this mechanism be minimized as much as possible. The best solution to this is to ensure that appropriate ingredients, both high in quality and purity, are chosen and used throughout the entire drug product lifecycle.
PharmaCyte Biotech recently announced it is about to embark upon a planned US FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the US, and with that journey comes the….
Catalent, Inc. recently announced it has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of…..